AstraZeneca Expands Partnership with Korean Biotechs via Strategic Cooperation

AstraZeneca is expanding its cooperation with Korean biotechs, bolstering its partnership with local companies. This move marks a strategic shift for the pharmaceutical giant in its pursuit of external innovation.

AstraZeneca has made significant progress in strengthening its collaboration with Korean biotech companies. According to latest reports, the partnership has seen considerable growth, indicating a strong foundation for future collaborations.

This strategic cooperation will enable AstraZeneca to tap into the expertise of Korean biotech firms, accelerating its search for groundbreaking discoveries and innovations.

AstraZeneca's efforts are not limited to Korea as the news indicates. According to the article, AstraZeneca is focusing on external innovation outside of single-asset licensing, implying a broadened approach to partnerships and investments.

However, AstraZeneca's stock performance has seen a decline, with its share price trading at below £135, sparking questions regarding its undervaluation and potential. Nonetheless, this will not hinder the company's strategic push in the biotechnology sector.